Racura Oncology

Dr Daniel Tillett

Dr Peter Smith

Dr Serge Scrofani

Dr Megan Baldwin

Innovative lead drug - RC220

Significant Market Opportunity

Three ongoing clinical trials

Focused on meaningful outcomes 

Why Invest

Updates

Announcements

Home

Inter

Racura Oncology InvestorHub

We invite shareholders and interested parties to engage with the Raucura Oncology leadership team via our interactive Investor Hub.

In late 2025, Racura made a breakthrough discovery in how bisantrene worked. While it had been known to bind to DNA, closer study revealed that it functioned as a G4-DNA & RNA binder able to targeting the key cancer growth regulator MYC - often hailed the ‘Holy Grail’ of cancer targets. 

Resources